Mayumi Ueta- Department of Ophthalmology, Kyoto Prefectural University of Medicine, Kyoto, Japan
Stevens-Johnson syndrome (SJS)/toxic epidermal necrolysis (TEN) is an acute inflammatory vesiculobullous reaction of the mucosa of the ocular surface, oral cavity, and genitals, and of the skin. Severe ocular complications (SOC) are observed in about half of SJS/TEN patients diagnosed by dermatologists and in burn units. Ophthalmologists treat SOC, and they tend to encounter the patients not only in the acute stage, but also in the chronic stage. Our investigation of the pathogenesis of SJS/TEN with SOC led us to suspect that abnormal innate mucosal immunity contributes to the ocular surface inflammation seen in SJS/TEN with SOC. We confirmed that cold medicines such as NSAIDs and multi-ingredient cold medications are the main causative drugs for SJS/TEN with SOC. Single nucleotide polymorphism (SNP) association analysis of cold medicine-related SJS/TEN with SOC showed that the Toll-like receptor 3 (TLR3)-, the prostaglandin-E receptor 3 (PTGER3)-, and the IKZF1 gene were significantly associated with SNPs and that these genes could regulate mucocutaneous inflammation including that of the ocular surface. We also examined the tear cytokines of SJS/TEN with SOC in the chronic stage and found that IL-8, IL-6, IFN-γ, RANTES, eotaxin, and MIP-1β were significantly upregulated in SJS/TEN with SOC in the chronic stage. Only IP-10 was significantly downregulated in SJS/TEN with SOC in the chronic stage. This mini-review summarizes the pathological mechanisms that we identified as underlying the development of SJS/TEN with SOC.
Introduction
Stevens-Johnson syndrome (SJS) is an acute inflammatory vesiculobullous reaction of the skin, the mucosa of the ocular surface, the oral cavity, and of the genitals; its severe phenotype is called toxic epidermal necrolysis (TEN).
Ophthalmologists tend to encounter the patients in the chronic stage, they can find it difficult to differentiate between SJS and TEN because the vesiculobullous skin lesions present in the acute stage have healed, so they tend to report SJS and TEN with severe ocular complications (SOC) broadly as “ophthalmic SJS” (1).
Approximately half of all SJS/TEN patients diagnosed by dermatologists and in burn units presented with SOC, e.g., severe conjunctivitis with pseudomembrane and ocular surface epithelial defects in the acute stage (2). When ophthalmologists encounter patients in the chronic stage, based on a confirmed history of acute-onset high fever, serious mucocutaneous illness with skin eruptions, and involvement of at least two mucosal sites including the ocular surface and ocular sequelae, e.g., severe dry eye, symblepharon, trichiasis, conjunctival inversion to the cornea, their diagnosis tends to be SJS/TEN (1, 3–6). SJS/TEN patients with severe conjunctivitis, epithelial defects, and pseudomembrane on the ocular surface in the acute stage often suffer serious ocular sequelae such as severe dry eye and vision disturbance that affect their daily life (7).
We reported cold medicines, including multi-ingredient cold medications and NSAIDs, as the main causative drugs of SJS/TEN with SOC (1, 4–6, 8, 9). About 80% of the SJS/TEN with SOC patients treated at the Kyoto Prefectural University of Medicine developed SJS/TEN within several days after taking medicines to combat the common cold (1, 4–6, 8–11).
We also observed that patients with SJS/TEN with SOC presented with opportunistic infection of the ocular surface by bacteria, especially MRSA and MRSE. The MRSA and MRSE detection rate was higher on the ocular surface of patients with SJS/TEN with SOC than in individuals with other devastating ocular surface disorders (12). SJS/TEN with SOC patients presented with persistent inflammation of the ocular surface even in the chronic stage. Their ocular surface inflammation was exacerbated by colonization with MRSA and MRSE, although, under normal conditions, colonization with these bacteria need not elicit ocular surface inflammation (1). Based on these observations we considered the possibility of an association between a disordered mucosal innate immune response and SJS/TEN with SOC. We postulated that a balance between the mucosal innate immunity of the ocular surface and bacterial pathogenicity is important. When host mucosal innate immunity is normal, commensal bacteria are in a symbiotic relationship with the host, however, when the host mucosal innate immunity is compromised, commensal bacteria including MRSA and MRSE can become pathogenic and contribute to the ocular surface inflammation seen in SJS/TEN with SOC (1).
We have been investigating the pathogenesis of ophthalmic SJS for more than 10 years. This mini-review summarizes our research findings on the pathological mechanisms underlying SJS/TEN with SOC.
Genes Associated With SJS/TEN With SOC and Their Functions
Although SJS/TEN with SOC can be induced by drugs, not all patients taking these drugs develop SJS/TEN with SOC. Since the incidence of SJS with SOC is very low, we suspected a genetic predisposition (1, 3) and first performed single nucleotide polymorphism (SNP) association analysis using candidate genes associated with innate immunity. We also carried out genome-wide association studies (GWAS) and found several susceptibility genes for SJS/TEN with SOC. Thereupon we subjected some of these susceptibility genes to function analysis using mouse models.
TLR3
TLR3 recognizes double-stranded (ds) RNA, a component of the life-cycle of most viruses and mimics polyI:C. Among toll-like receptors (TLRs) TLR1—TLR10, TLR3 is expressed most intensely on the ocular surface epithelium. Its expression there is stronger than in mononuclear cells and we documented that TLR3 was able to induce many cytokines and genes on the ocular surface (13–15). SNP association analysis of TLR3 revealed that in Japan, TLR3 SNPs were significantly associated with SJS/TEN with SOC (8, 16–18).
Using a murine model of experimental allergic conjunctivitis as a model for ocular surface inflammation, we examined TLR3 gene function in TLR3 knock-out (KO)- and TLR3 transgenic (TLR3Tg) mice. We found that ocular surface inflammation was significantly reduced in TLR3 KO- and significantly increased in TLR3Tg mice (19). We also reported that TLR3 was expressed in the epidermis of the skin and that in a murine model of contact dermatitis, the severity of skin inflammation was significantly lower in TLR3 KO mice and significantly greater in TLR3Tg mice than in wild-type mice (20). Yasuike et al. (21) made the same findings in a murine atopic dermatitis model as we did using a murine model of ocular surface inflammation and contact dermatitis. These findings led us to suspect that TLR3 was able to positively regulate mucocutaneous inflammation of the skin and ocular surface (22) and might contribute the mucocutaneous inflammation seen in patients with SJS/TEN with SOC (22).
EP3
GWAS and additional analysis revealed that the prostaglandin E receptor 3 (PTGER3) gene was significantly associated with CM-SJS/TEN with SOC in Japan and Korea (4, 17, 23).
We performed function analysis of the PTGER3 gene whose protein is EP3, one of four receptors (EP1, EP2, EP3, and EP4) of prostaglandin E2. Cold medicine ingredients, e.g., acetaminophen and NSAIDs, e.g., ibuprofen and loxoprofen, suppress the production of prostanoids including PGE2 (1, 8, 22). PGE2 acts on EP3 in the ocular surface epithelium and epidermis, and negatively regulates ocular surface- and skin inflammation (24, 25). Kunikata et al. (26) reported that EP3 negatively regulates respiratory tract inflammation. We suggested that the suppression of PGE2 production by cold medicines might contribute to the pathogenesis and onset of CM-SJS/TEN with SOC (1, 4, 6, 8, 11, 22) because PGE2 acts on EP3 and negatively regulates mucocutaneous inflammation (24–26).
Our examination of EP3 protein expression on the human ocular surface showed that EP3 protein levels were much lower in the conjunctival epithelium of patients with SJS/TEN with SOC than in the controls, i.e., patients with conjunctival chalasis or chemical burns (27). We postulated that EP3 expression might be strongly down-regulated on the ocular surface of patients with SJS/TEN with SOC and contribute to ocular surface inflammation in these patients (27).
IKZF1
Using the Affymetrix AXIOM genome-wide ASI 1 array we performed GWAS of samples from 117 Japanese patients with CM-SJS/TEN with SOC and 691 controls (28). The IKZF1 gene was strongly associated with CM-SJS/TEN with SOC (6) and our meta-analysis of samples from Japanese-, Korean-, Indian-, and Brazilian patients showed a significant genome-wide association between CM-SJS/TEN with SOC and IKZF1 [rs4917014 (G vs. T), odds ratio (OR) = 0.5, p = 8.5 × 10−11] (6), suggesting that IKZF1 may be a universal marker for susceptibility to this disease (6).
Function analysis of IKZF1 SNPs revealed that the ratio of the splicing isoforms Ik2/Ik1 may be affected by these SNPs, which are significantly associated with susceptibility to CM-SJS/TEN with SOC and that the function of Ikaros, the protein of IKZF1, might be enhanced in CM-SJS/TEN with SOC (6). Ikaros, a transcription factor that regulates numerous biological events, has been reported to regulate important cell-fate decisions involved in the development of adaptive immunity (29).
We suspected that the epithelium played a role in the pathobiology of CM-SJS/TEN with SOC (1) because TLR3 was strongly expressed in ocular surface epithelial cells (13, 14) and keratinocytes (20), and it regulated ocular surface inflammation (19) and dermatitis (20, 21), and because EP3, which negatively regulates mucocutaneous inflammation, was dominantly expressed on the ocular surface epithelium (24), epidermis (25), and the airway epithelium (26).
To address this issue we produced K5-Ikzf1-EGFP transgenic mice (Ikzf1Tg) by introducing the Ik1 isoform into cells expressing keratin 5, which is expressed in epithelial tissues such as the epidermis and conjunctiva. We found that mucocutaneous inflammation was exacerbated in Ikzf1Tg mice; they developed dermatitis and some developed blepharoconjunctivitis. Histological analysis showed not only dermatitis but also tissue inflammation of their tongues, blepharoconjunctiva, and paronychia (30) as did patients with SJS/TEN with SOC in the acute stage of the disease (1) (Figure 1).
Figure 1. Finding of K5-Ikzf1-EGFP transgenic mice (Ikzf1Tg). Ikzf1Tg mice were introduced the Ik1 isoform into cells expressing keratin 5, which is expressed in epithelial tissues such as the epidermis and conjunctiva. Ikzf1Tg mice developed dermatitis and some developed blepharoconjunctivitis (A). Histological analysis showed not only dermatitis but also tissue inflammation of their tongues, blepharoconjunctiva, and paronychia (B) as did patients with SJS/TEN with SOC in the acute stage of the disease (C). Reprinted with permission from Ueta et al. (10, 28).
As our findings suggested that IKZF1 plays a critical role in maintaining mucocutaneous homeostasis, we proposed that the gene participates in the exacerbation of the mucocutaneous inflammation seen in patients with CM-SJS/TEN with SOC (11, 22, 30).
Gene–Gene Interactions
Considering the contrasting roles of Ptger3 and TLR3 in mucocutaneous inflammation, we looked for an unknown functional interaction between EP3, the protein of Ptger3, and TLR3. We found that EP3 negatively regulated TLR3-dependent ocular surface inflammation (8, 11, 17, 22). Ocular surface inflammation in TLR3/Ptger3-double-KO mice was decreased to a level similar to that in TLR3-KO mice and significantly lower than in wild-type mice (17). Moreover, in conjunctival epithelial cells the EP3 agonist suppressed the production and mRNA expression of polyI:C-induced various cytokines such as RANTES, IP-10 (31), and MCP-1 (32), and TSLP (33).
On the other hand, the expression of IKZF1 mRNA was upregulated by TLR3 in human epidermal keratinocytes and conjunctival epithelial cells (30), suggesting an interaction between TLR3 and IKZF1 (30). Furthermore, since CM-SJS/TEN with SOC developed in individuals who had taken cold medications to combat the common cold due to viral or mycoplasma, we suspect that not only cold medicines and susceptibility genes such as TLR3, PTGER3, and IKZF1, but also some microbial infections with, for example viruses or mycoplasma, are important and necessary to trigger the onset of SJS/TEN with SOC (1, 8, 11) (Figure 2).
Figure 2. Gene–gene interactions. The susceptibility genes such as TLR3, PTGER3, and IKZF1, might contribute the mucocutaneous inflammation of SJS/TEN with SOC. Reprinted with permission from Ueta et al. (19).
Other Studies
We also examined tear cytokines of SJS/TEN with SOC in the chronic stage. IL-8, IL-6, IFN-γ, RANTES, eotaxin, and MIP-1β were significantly upregulated in SJS/TEN with SOC in the chronic stage, while only interferon-γ-inducible protein 10 (IP-10) was significantly downregulated (34). In human corneal and conjunctival epithelial cells, IP-10 is highly induced by the TLR3 ligand polyI:C (15), possibly as a consequence of abnormal innate immunity that involves the presence of TLR3 in SJS/TEN with SOC (1, 8, 11).
Moreover, we found that in SJS/TEN patients with SOC, IL-8 was significantly upregulated in eyes with conjunctivalization, neovascularization, or opacification (35). Granzyme B (GrzB) was upregulated in eyes with keratinization, IL-1α in eyes with opacification, and IP-10 was downregulated in eyes with conjunctivalization or neovascularization (all: p < 0.05) (35). These observations suggest that IL-8 and IP-10 are involved in conjunctivalization and neovascularization, and that GrzB is involved in keratinization (35).
Discussion
This mini review suggests that SJS/TEN with SOC is pathogenetically related with a disordered innate immune response.
We identified TLR3, PTGER3, and IKZF1 as susceptibility genes for SJS/TEN with SOC, demonstrated that they are able to regulate mucocutaneous inflammation, including ocular surface inflammation, and reported functional interactions between TLR3 and PTGER3, or TLR3 and IKZF1.
Since CM-SJS/TEN with SOC is a rare and probably has a complex genetic background, it is reasonable to posit multiplicative gene interactions. Multiple susceptibility genes for CM-SJS/TEN with SOC, including innate immunity-related genes such as TLR3, may also be involved in functional networks. The absence of a balance between these genes results in abnormal innate immunity and may trigger the development of mucocutaneous inflammation seen in patients with CM-SJS/TEN with SOC (1, 8, 11).
We reported that 80% of our SJS/TEN with SOC patients developed SJS/TEN within several days after taking cold medicines including multi-ingredient cold medications and non-steroidal anti-inflammatory drugs (NSAIDs) to combat the common cold (1, 4–6), suggesting that cold medicines are major causative drugs for SJS/TEN with SOC. We have also suggested that the onset of CM-SJS/TEN with SOC was associated not only with certain drugs but also with putative microbial infection (1, 8, 11, 22).
Moreover, we also analyzed the possible association between human leukocyte antigen (HLA) genotypes and cold medicine-related SJS/TEN (CM-SJS/TEN) with SOC, and found that in the Japanese it was strongly associated with HLA-A*02:06 and significantly associated with HLA-B*44:03 (5). Interestingly, these HLA genotypes were not involved in CM-SJS/TEN without SOC (5), suggesting that the genetic predisposition such as the HLA genotype might be different in SJS/TEN patients with/without SOC (5). We also found that CM-SJS/TEN with SOC was significantly associated with HLA-B*44:03 in Indian- and Brazilian-, especially Caucasian Brazilian patients, and HLA-A*02:06 was associated with CM-SJS/TEN with SOC in Koreans (36).
Based on the totality of the above-cited observations we suggest that in addition to microbial infections and cold medicines, the combination of multiple gene polymorphisms and their interactions might result in abnormal innate immunity and contribute strongly to the onset of CM-SJS/TEN with SOC (1, 8, 11).
We looked for susceptibility genes for SJS/TEN with SOC in the human genome, and investigated their function in a mouse model of ocular surface inflammation and dermatitis. We demonstrated that TLR3, PTGER3, and IKZF1, susceptibility genes for SJS/TEN with SOC, were able to regulate mucocutaneous inflammation (4, 6, 17, 19–21, 23, 30). Using human samples, we found that EP3 protein levels were much lower in the conjunctival epithelium of patients with SJS/TEN with SOC than in our control subjects (27), and that IP-10, which is greatly induced by the TLR3 ligand on the ocular surface epithelium, was significantly downregulated in the tears of patients with SJS/TEN in the chronic stage (34). These findings on human subjects support our hypothesis that abnormal mucosal innate immunity contributes to the ocular surface inflammation of SJS/TEN with SOC patients (1, 8, 11). Additional studies that focus on the innate immunity of the ocular surface are needed to elucidate the pathogenesis of SJS/TEN with SOC.
Author Contributions
MU wrote this mini review article.
Funding
This work was supported by grants-in-aid from the Ministry of Education, Culture, Sports, Science, and Technology of the Japanese government, by the JSPS Core-to-Core Program, A. Advanced Research Networks, and partly supported by grants-in-aid for scientific research from the Japanese Ministry of Health, Labor, and Welfare.
Conflict of Interest
The author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher's Note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
1. Ueta M, Kinoshita S. Ocular surface inflammation is regulated by innate immunity. Prog Retin Eye Res. (2012) 31:551–75. doi: 10.1016/j.preteyeres.2012.05.003
2. Sotozono C, Ueta M, Nakatani E, Kitami A, Watanabe H, Sueki H, et al. Predictive factors associated with acute ocular involvement in Stevens-Johnson syndrome and toxic epidermal necrolysis. Am J Ophthalmol. (2015) 160:228–37 e2. doi: 10.1016/j.ajo.2015.05.002
3. Ueta M, Sotozono C, Tokunaga K, Yabe T, Kinoshita S. Strong association between HLA-A*0206 and Stevens-Johnson syndrome in the Japanese. Am J Ophthalmol. (2007) 143:367–8. doi: 10.1016/j.ajo.2006.09.029
4. Ueta M, Sotozono C, Nakano M, Taniguchi T, Yagi T, Tokuda Y, et al. Association between prostaglandin E receptor 3 polymorphisms and Stevens-Johnson syndrome identified by means of a genome-wide association study. J Allergy Clin Immunol. (2010) 126:1218–25.e10. doi: 10.1016/j.jaci.2010.08.007
5. Ueta M, Kaniwa N, Sotozono C, Tokunaga K, Saito Y, Sawai H, et al. Independent strong association of HLA-A*02:06 and HLA-B*44:03 with cold medicine-related Stevens-Johnson syndrome with severe mucosal involvement. Sci Rep. (2014) 4:4862. doi: 10.1038/srep04862
6. Ueta M, Sawai H, Sotozono C, Hitomi Y, Kaniwa N, Kim MK, et al. IKZF1, a new susceptibility gene for cold medicine-related Stevens-Johnson syndrome/toxic epidermal necrolysis with severe mucosal involvement. J Allergy Clin Immunol. (2015) 135:1538–45.e17. doi: 10.1016/j.jaci.2014.12.1916
7. Sotozono C, Ang LP, Koizumi N, Higashihara H, Ueta M, Inatomi T, et al. New grading system for the evaluation of chronic ocular manifestations in patients with Stevens-Johnson syndrome. Ophthalmology. (2007) 114:1294–302. doi: 10.1016/j.ophtha.2006.10.029
8. Ueta M. Cold medicine-related Stevens-Johnson syndrome/toxic epidermal necrolysis with severe ocular complications-phenotypes and genetic predispositions. Taiwan J Ophthalmol. (2016) 6:108–18. doi: 10.1016/j.tjo.2016.06.001
9. Wakamatsu TH, Ueta M, Tokunaga K, Okada Y, Loureiro RR, Costa KA, et al. Human leukocyte antigen class I genes associated with Stevens-Johnson syndrome and severe ocular complications following use of cold medicine in a Brazilian population. JAMA Ophthalmol. (2017) 135:355–60. doi: 10.1001/jamaophthalmol.2017.0074
10. Jongkhajornpong P, Lekhanont K, Pisuchpen P, Chantaren P, Puangsricharern V, Prabhasawat P, et al. Association between HLA-B*44:03-HLA-C*07:01 haplotype and cold medicine-related Stevens-Johnson syndrome with severe ocular complications in Thailand. Br J Ophthalmol. (2018) 102:1303–7. doi: 10.1136/bjophthalmol-2017-311823
11. Ueta M. Stevens-Johnson syndrome/toxic epidermal necrolysis with severe ocular complications. Expert Rev Clin Immunol. (2020) 16:285–91. doi: 10.1080/1744666X.2020.1729128
12. Sotozono C, Inagaki K, Fujita A, Koizumi N, Sano Y, Inatomi T, et al. Methicillin-resistant Staphylococcus aureus and methicillin-resistant Staphylococcus epidermidis infections in the cornea. Cornea. (2002) 21:S94–S101. doi: 10.1097/01.ico.0000263127.84015.3f
13. Ueta M, Hamuro J, Kiyono H, Kinoshita S. Triggering of TLR3 by polyI:C in human corneal epithelial cells to induce inflammatory cytokines. Biochem Biophys Res Commun. (2005) 331:285–94. doi: 10.1016/j.bbrc.2005.02.196
14. Ueta M, Kinoshita S. Innate immunity of the ocular surface. Brain Res Bull. (2010) 81:219–28. doi: 10.1016/j.brainresbull.2009.10.001
15. Ueta M, Mizushima K, Yokoi N, Naito Y, Kinoshita S. Gene-expression analysis of polyI:C-stimulated primary human conjunctival epithelial cells. Br J Ophthalmol. (2010) 94:1528–32. doi: 10.1136/bjo.2010.180554
16. Ueta M, Sotozono C, Inatomi T, Kojima K, Tashiro K, Hamuro J, et al. Toll-like receptor 3 gene polymorphisms in Japanese patients with Stevens-Johnson syndrome. Br J Ophthalmol. (2007) 91:962–5. doi: 10.1136/bjo.2006.113449
17. Ueta M, Tamiya G, Tokunaga K, Sotozono C, Ueki M, Sawai H, et al. Epistatic interaction between Toll-like receptor 3 (TLR3) and prostaglandin E receptor 3 (PTGER3) genes. J Allergy Clin Immunol. (2012) 129:1413–6 e11. doi: 10.1016/j.jaci.2012.01.069
18. Ueta M, Tokunaga K, Sotozono C, Sawai H, Tamiya G, Inatomi T, et al. HLA-A*0206 with TLR3 polymorphisms exerts more than additive effects in Stevens-Johnson syndrome with severe ocular surface complications. PLoS One. (2012) 7:e43650. doi: 10.1371/journal.pone.0043650
19. Ueta M, Uematsu S, Akira S, Kinoshita S. Toll-like receptor 3 enhances late-phase reaction of experimental allergic conjunctivitis. J Allergy Clin Immunol. (2009) 123:1187–9. doi: 10.1016/j.jaci.2009.03.008
20. Nakamura N, Tamagawa-Mineoka R, Ueta M, Kinoshita S, Katoh N. Toll-like receptor 3 increases allergic and irritant contact dermatitis. J Invest Dermatol. (2015) 135:411–7. doi: 10.1038/jid.2014.402
21. Yasuike R, Tamagawa-Mineoka R, Ueta M, Nakamura N, Kinoshita S, Katoh N. The role of toll-like receptor 3 in chronic contact hypersensitivity induced by repeated elicitation. J Dermatol Sci. (2017) 88:184–91. doi: 10.1016/j.jdermsci.2017.07.017
22. Ueta M. Results of detailed investigations into Stevens-Johnson syndrome with severe ocular complications. Invest Ophthalmol Vis Sci. (2018) 59:DES183–DES91. doi: 10.1167/iovs.17-23537
23. Ueta M, Tokunaga K, Sotozono C, Sawai H, Yoon KC, Kim MK, et al. HLA-A*02:06 and PTGER3 polymorphism exerts additive effects in cold medicine-related Stevens-Johnson syndrome with severe ocular complications. Hum Genome Variation. (2015) 2:15023. doi: 10.1038/hgv.2015.23
24. Ueta M, Matsuoka T, Narumiya S, Kinoshita S. Prostaglandin E receptor subtype EP3 in conjunctival epithelium regulates late-phase reaction of experimental allergic conjunctivitis. J Allergy Clin Immunol. (2009) 123:466–71. doi: 10.1016/j.jaci.2008.09.044
25. Honda T, Matsuoka T, Ueta M, Kabashima K, Miyachi Y, Narumiya S. Prostaglandin E(2)-EP(3) signaling suppresses skin inflammation in murine contact hypersensitivity. J Allergy Clin Immunol. (2009) 124:809–18.e2. doi: 10.1016/j.jaci.2009.04.029
26. Kunikata T, Yamane H, Segi E, Matsuoka T, Sugimoto Y, Tanaka S, et al. Suppression of allergic inflammation by the prostaglandin E receptor subtype EP3. Nat Immunol. (2005) 6:524–31. doi: 10.1038/ni1188
27. Ueta M, Sotozono C, Yokoi N, Inatomi T, Kinoshita S. Prostaglandin E receptor subtype EP3 expression in human conjunctival epithelium and its changes in various ocular surface disorders. PLoS One. (2011) 6:e25209. doi: 10.1371/journal.pone.0025209
28. Goncalves AL, de Araujo KC, Carvalho EF, Ueta MT, Costa-Cruz JM. Specific IgG and immune complex responses to parthenogenetic females and eggs of nematode Strongyloides venezuelensis for the diagnosis of immunosuppression in infected rats. J Helminthol. (2016) 90:342–6. doi: 10.1017/S0022149X15000346
29. John LB, Ward AC. The Ikaros gene family: transcriptional regulators of hematopoiesis and immunity. Mol Immunol. (2011) 48:1272–8. doi: 10.1016/j.molimm.2011.03.006
30. Ueta M, Hamuro J, Nishigaki H, Nakamura N, Shinomiya K, Mizushima K, et al. Mucocutaneous inflammation in the Ikaros Family Zinc Finger 1-keratin 5-specific transgenic mice. Allergy. (2018) 73:395–404. doi: 10.1111/all.13308
31. Ueta M, Matsuoka T, Yokoi N, Kinoshita S. Prostaglandin E2 suppresses polyinosine-polycytidylic acid (polyI:C)-stimulated cytokine production via prostaglandin E2 receptor (EP) 2 and 3 in human conjunctival epithelial cells. Br J Ophthalmol. (2011) 95:859–63. doi: 10.1136/bjo.2010.199679
32. Ueta M, Sotozono C, Yokoi N, Kinoshita S. Downregulation of monocyte chemoattractant protein 1 expression by prostaglandin E(2) in human ocular surface epithelium. Arch Ophthalmol. (2012) 130:249–51. doi: 10.1001/archopthalmol.2011.1472
33. Ueta M, Matsuoka T, Yokoi N, Kinoshita S. Prostaglandin E receptor subtype EP3 downregulates TSLP expression in human conjunctival epithelium. Br J Ophthalmol. (2011) 95:742–3. doi: 10.1136/bjo.2010.188748
34. Ueta M, Nishigaki H, Sotozono C, Kinoshita S. Downregulation of interferon-gamma-induced protein 10 in the tears of patients with Stevens-Johnson syndrome with severe ocular complications in the chronic stage. BMJ Open Ophthalmol. (2017) 1:e000073. doi: 10.1136/bmjophth-2017-000073
35. Yoshikawa Y, Ueta M, Nishigaki H, Kinoshita S, Ikeda T, Sotozono C. Predictive biomarkers for the progression of ocular complications in chronic Stevens-Johnson syndrome and toxic Eeidermal necrolysis. Sci Rep. (2020) 10:18922. doi: 10.1038/s41598-020-76064-8
Keywords: Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), severe ocular complications (SOC), cold medicine, TLR3, EP3, IKZF1
Citation: Ueta M (2021) Pathogenesis of Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis With Severe Ocular Complications. Front. Med. 8:651247. doi: 10.3389/fmed.2021.651247
Received: 09 January 2021; Accepted: 25 October 2021;
Published: 17 November 2021.
Edited by:
Hon Shing Ong, Singapore National Eye Center, SingaporeReviewed by:
Wen-Hung Chung, Chang Gung Memorial Hospital, TaiwanOmer Iqbal, Loyola University Chicago, United States
Copyright © 2021 Ueta. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Mayumi Ueta, mueta@koto.kpu-m.ac.jp